Genmab — Juni 2020
-
Brexit har ingen speciel betydning for Genmab.
-
Novo ser også fin ud.
-
It is only a very short data follow up at the moment, on the other hand it is very good data and very early responses, which is particularly important for Amyloidosis in order to prevent organ damage, so maybe that is enough for FDA to accept a filing?
-
Genmab A/S (GMAB) Remains Dominant Post EHA - Suntrust https://www.streetinsider.com/Analyst+Comments/Genmab+AS+(GMAB)+Remains+Dominant+Post+EHA+-+Suntrust/17004986.html
-
Apropos HSBC så er deres nye analyse da også kun til at grine af. Hvis man rent (aktie)intellektuelt er bagefter - ja så gælder det da om at gøre en dyd af det - for dyr - så er der en lille chance for at man får ret fremadrettet. Det må være logikken for dummies. Men tænk lige på hvilken fejlrådgivning de har præsteret i 3 år. De har frataget investorerne muligheden for at tjene gode penge. Mon ikke det samme sker fremadrettet.
-
HSBC uddyber forudsætninger for nyt kursmål
-
-
Dette citat er jeg helt enig med HSBC "Vi beundrer fortsat videnskaben, strategien og hvordan selskabet bliver kørt"
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind